SG11201401536QA - Methods for improving inflammatory bowel disease diagnosis - Google Patents
Methods for improving inflammatory bowel disease diagnosisInfo
- Publication number
- SG11201401536QA SG11201401536QA SG11201401536QA SG11201401536QA SG11201401536QA SG 11201401536Q A SG11201401536Q A SG 11201401536QA SG 11201401536Q A SG11201401536Q A SG 11201401536QA SG 11201401536Q A SG11201401536Q A SG 11201401536QA SG 11201401536Q A SG11201401536Q A SG 11201401536QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- inflammatory bowel
- bowel disease
- disease diagnosis
- improving inflammatory
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/49—Platelet-derived growth factor [PDGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70542—CD106
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550293P | 2011-10-21 | 2011-10-21 | |
US201161553853P | 2011-10-31 | 2011-10-31 | |
US201161567096P | 2011-12-05 | 2011-12-05 | |
US201161570271P | 2011-12-13 | 2011-12-13 | |
PCT/US2012/061202 WO2013059732A1 (en) | 2011-10-21 | 2012-10-19 | Methods for improving inflammatory bowel disease diagnosis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201401536QA true SG11201401536QA (en) | 2014-05-29 |
Family
ID=48141435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201401536QA SG11201401536QA (en) | 2011-10-21 | 2012-10-19 | Methods for improving inflammatory bowel disease diagnosis |
Country Status (10)
Country | Link |
---|---|
US (2) | US8715943B2 (en) |
EP (1) | EP2769321B1 (en) |
JP (1) | JP2015502740A (en) |
AU (1) | AU2012325798B2 (en) |
CA (1) | CA2852954A1 (en) |
HK (1) | HK1200933A1 (en) |
IL (1) | IL232167A0 (en) |
MX (1) | MX352274B (en) |
SG (1) | SG11201401536QA (en) |
WO (1) | WO2013059732A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
AU2010236568B2 (en) | 2009-04-14 | 2015-08-27 | Société des Produits Nestlé S.A. | Inflammatory bowel disease prognostics |
WO2015067913A1 (en) | 2013-11-07 | 2015-05-14 | Diagnodus Limited | Biomarkers |
RU2013154566A (en) | 2011-05-10 | 2015-06-20 | Нестек С.А. | METHODS FOR ANALYSIS OF THE DISEASE ACTIVITY PROFILE FOR THE PURPOSE OF INDIVIDUAL TREATMENT |
BR112015024752A2 (en) | 2013-03-27 | 2017-07-18 | Cedars Sinai Medical Center | mitigation and reversal of fibrosis and inflammation through inhibition of tl1a function and related signaling pathways |
WO2014182689A1 (en) * | 2013-05-06 | 2014-11-13 | Yacyshyn Bruce R | Method of using biomarkers in predicting inflammatory bowel disease |
MX367046B (en) * | 2013-05-24 | 2019-08-02 | Soc Des Produits Nestle S A Star | Pathway specific markers for diagnosing irritable bowel syndrome. |
EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
US11568982B1 (en) | 2014-02-17 | 2023-01-31 | Health at Scale Corporation | System to improve the logistics of clinical care by selectively matching patients to providers |
US11227667B2 (en) * | 2014-07-11 | 2022-01-18 | Matatu, Inc. | Use of a gut microbiome as a predictor of animal growth or health |
CN104131102B (en) * | 2014-08-07 | 2016-06-15 | 马飞 | A kind of judge that NSCLC patient is to the test kit of Gefitinib therapeutic response |
US11809501B2 (en) * | 2014-08-28 | 2023-11-07 | Ebay Inc. | Systems, apparatuses, and methods for providing a ranking based recommendation |
EP3227685A1 (en) * | 2014-12-02 | 2017-10-11 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
JP2018507470A (en) | 2015-01-20 | 2018-03-15 | ナントミクス,エルエルシー | System and method for predicting response to chemotherapy for high-grade bladder cancer |
CA2978708A1 (en) * | 2015-03-03 | 2016-09-09 | Nantomics, Llc | Ensemble-based research recommendation systems and methods |
US11037070B2 (en) * | 2015-04-29 | 2021-06-15 | Siemens Healthcare Gmbh | Diagnostic test planning using machine learning techniques |
US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
CN109462996A (en) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | The method for diagnosing inflammatory bowel disease by RNASET2 |
US11549146B2 (en) | 2016-05-20 | 2023-01-10 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
JP7111322B2 (en) | 2016-12-02 | 2022-08-02 | 国立大学法人 東京大学 | Antibodies against fibrosis-related molecules and their medical applications |
US10811126B2 (en) * | 2016-12-14 | 2020-10-20 | Tracy Warren | System and methods for developing and using a microbiome-based action component for patient health |
US10409734B1 (en) * | 2017-03-27 | 2019-09-10 | Symantec Corporation | Systems and methods for controlling auxiliary device access to computing devices based on device functionality descriptors |
CN108784666B (en) * | 2017-05-04 | 2023-01-13 | 深圳市生码医疗科技有限公司 | Accurate medical system for continuously monitoring cardiovascular and data processing method |
KR20200009095A (en) | 2017-05-31 | 2020-01-29 | 프로메테우스 바이오사이언시즈, 인크. | How to evaluate mucosal healing in patients with Crohn's disease |
WO2019195146A1 (en) * | 2018-04-03 | 2019-10-10 | Boston Scientific Scimed, Inc. | Systems and methods for diagnosing and/or monitoring disease |
WO2020009949A1 (en) * | 2018-07-05 | 2020-01-09 | Boston Scientific Scimed, Inc. | Devices, systems, and methods for determining inflammation and/or fibrosis |
CA3108719A1 (en) * | 2018-08-21 | 2020-02-27 | Bruce R. Yacyshyn | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
WO2020113116A1 (en) * | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Methods of stratifying and treating a sub-population of inflammatory bowel disease patients |
WO2020117795A1 (en) * | 2018-12-04 | 2020-06-11 | Prometheus Biosciences, Inc. | Assessment and monitoring of mucosal healing in children and adults with crohn's disease |
EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | Data compression and communication using machine learning |
WO2020219549A1 (en) * | 2019-04-23 | 2020-10-29 | Cedars-Sinai Medical Center | Methods and systems for assessing inflammatory disease with deep learning |
JP2022532381A (en) * | 2019-05-16 | 2022-07-14 | プロサイセデクス インコーポレイティド | Analytical detection methods for VCAM-1 and calprotectin |
CN110373457B (en) * | 2019-06-20 | 2023-03-14 | 镇江市第一人民医院 | mRNA marker for ulcerative colitis diagnosis and application thereof |
CN111417124A (en) * | 2019-06-28 | 2020-07-14 | 西南交通大学 | Method for sensing frequency spectrum in cognitive wireless network environment |
US11610679B1 (en) * | 2020-04-20 | 2023-03-21 | Health at Scale Corporation | Prediction and prevention of medical events using machine-learning algorithms |
US20230279491A1 (en) * | 2020-06-03 | 2023-09-07 | Cedars-Sinai Medical Center | Treatments for a sub-population of inflammatory bowel disease patients |
WO2022061346A1 (en) * | 2020-09-16 | 2022-03-24 | Northwestern University | Classification of functional lumen imaging probe data |
CA3194324A1 (en) * | 2020-10-05 | 2022-04-14 | Dermot MCGOVERN | Methods and systems for stratifying inflammatory bowel disease patients |
US20240044916A1 (en) * | 2020-12-11 | 2024-02-08 | Icahn School Of Medicine At Mount Sinai | Methods of monitoring inflammatory bowel diseases |
CR20230445A (en) | 2021-02-17 | 2023-11-14 | Prometheus Biosciences Inc | Anti-cd30l antibodies and uses thereof |
WO2023047257A1 (en) * | 2021-09-22 | 2023-03-30 | Janssen Research & Development, Llc | Automated estimation of ulcerative colitis severity from endoscopy videos using ordinal multi-instance learning |
WO2023147139A1 (en) * | 2022-01-28 | 2023-08-03 | University Of Southern California | Identifying non-disease patients using a disease related assay and analysis in the liquid biopsy |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4277250A (en) | 1979-12-10 | 1981-07-07 | Baylor College Of Medicine | Methods for detecting and quantifying occult blood |
JPH0684970B2 (en) | 1987-03-31 | 1994-10-26 | 株式会社京都医科学研究所 | Method of detecting occult blood in feces |
US5081040A (en) | 1987-06-29 | 1992-01-14 | Helena Laboratories Corporation | Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
JPH0736013B2 (en) | 1991-04-27 | 1995-04-19 | 一男 田畑 | Reagent for occult blood detection |
US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
US5830675A (en) | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
DK0615129T3 (en) | 1993-03-10 | 2000-08-07 | Cedars Sinai Medical Center | Methods for selective detection of perinuclear anti-neutrophil cytoplasmic antibody from ulcerative colitis or |
WO1995025809A1 (en) | 1994-03-23 | 1995-09-28 | Ohio University | Compacted nucleic acids and their delivery to cells |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5972901A (en) | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
US5844107A (en) | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
US5916748A (en) | 1996-04-12 | 1999-06-29 | Cedars-Sinai Medical Center | Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis |
US5932429A (en) | 1996-04-12 | 1999-08-03 | Cedars-Sinai Medical Center | Methods of diagnosing clinical subtypes of crohn's disease |
US6074835A (en) | 1996-04-12 | 2000-06-13 | Regents Of The Univ. Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1 |
US5750479A (en) | 1997-02-14 | 1998-05-12 | Bandon Corp. | Enclosed fluid system conditioner and process therefor |
AU4145597A (en) | 1997-02-20 | 1998-09-09 | Cedars-Sinai Medical Center | Ulcerative colitis panca secretory vesicle antigen and methods of using sa me |
US6218129B1 (en) | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
US6309643B1 (en) | 1999-04-30 | 2001-10-30 | The Regents Of The University Of California | IBD-associated microbial antigens and methods of using same |
AU5161800A (en) | 1999-05-24 | 2000-12-12 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
FR2802536B1 (en) | 1999-11-23 | 2003-06-13 | Chru Lille | SYNTHESIS OLIGOMANNOSIDES, THEIR PREPARATION AND THEIR USE FOR THE DETECTION OF ANTIBODIES AND THE PREVENTION OF INFECTIONS |
FR2806739B1 (en) | 2000-03-27 | 2005-02-18 | Fond Jean Dausset Ceph | GENES INVOLVED IN INFLAMMATORY BOWEL DISEASES AND THEIR USE |
US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
US7138237B1 (en) | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
US20020042388A1 (en) | 2001-05-01 | 2002-04-11 | Cooper Mark J. | Lyophilizable and enhanced compacted nucleic acids |
US6821739B2 (en) | 2000-10-13 | 2004-11-23 | The Regents Of The University Of California | Methods of diagnosing and treating Crohn's disease using Pseudomonas antigens |
US20020150626A1 (en) | 2000-10-16 | 2002-10-17 | Kohane Daniel S. | Lipid-protein-sugar particles for delivery of nucleic acids |
ES2486340T3 (en) | 2000-10-30 | 2014-08-18 | The Regents Of The University Of Michigan | Nucleic acids and Nod2 proteins |
AU2735002A (en) | 2000-10-30 | 2002-05-15 | Univ Michigan | Nod2 nucleic acids and proteins |
US7060442B2 (en) | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
US20050164929A1 (en) | 2000-11-06 | 2005-07-28 | Lupine Logic, Inc. | Methods of preventing and treating inflammatory bowel disease |
CA2427898C (en) | 2000-11-14 | 2017-08-15 | Techlab, Inc. | Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker |
CA2445947A1 (en) | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
CA2476755C (en) | 2001-12-17 | 2014-08-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US20030204507A1 (en) | 2002-04-25 | 2003-10-30 | Li Jonathan Qiang | Classification of rare events with high reliability |
US20040053263A1 (en) | 2002-08-30 | 2004-03-18 | Abreu Maria T. | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease |
EP1554580B1 (en) | 2002-10-25 | 2008-05-14 | Techlab, Inc. | Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel |
AU2003298703A1 (en) | 2002-11-22 | 2004-06-18 | Emory University | Diagnostic tests and methods for diagnosing inflammatory bowel disease |
US7662569B2 (en) | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
EP1617214A4 (en) | 2003-04-23 | 2008-01-23 | Eisai R&D Man Co Ltd | Method of creating disease prognosis model, method of predicting disease prognosis using the model, device for predicting disease prognosis using the model, its program, and recording medium |
US20040242972A1 (en) | 2003-05-28 | 2004-12-02 | General Electric Company | Method, system and computer product for prognosis of a medical disorder |
US20050060295A1 (en) | 2003-09-12 | 2005-03-17 | Sensory Networks, Inc. | Statistical classification of high-speed network data through content inspection |
US7439019B2 (en) | 2003-11-03 | 2008-10-21 | Duke University | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction |
CA2554836A1 (en) | 2004-02-05 | 2005-08-25 | Medtronic, Inc. | Methods and apparatus for identifying patients at risk for life threatening arrhythmias |
US20060154276A1 (en) | 2004-05-13 | 2006-07-13 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
US7759079B2 (en) | 2004-05-13 | 2010-07-20 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
WO2006012472A1 (en) | 2004-07-21 | 2006-02-02 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
EP2270512B1 (en) | 2004-12-08 | 2016-03-23 | Cedars-Sinai Medical Center | Methods for diagnosis of Crohn's disease |
WO2008109782A2 (en) | 2007-03-06 | 2008-09-12 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
US7873479B2 (en) | 2005-12-01 | 2011-01-18 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
US8153443B2 (en) | 2007-05-10 | 2012-04-10 | Cedars-Sinai Medical Center | Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease |
CA2719384A1 (en) | 2008-03-27 | 2009-10-01 | Jx Nippon Oil & Energy Corporation | Fuel cell system and method for load following operation of the same |
CA2794757A1 (en) | 2008-11-11 | 2010-05-20 | Prometheus Laboratories Inc. | Methods for prediction of inflammatory bowel disease (ibd) using serologic markers |
AU2010236568B2 (en) * | 2009-04-14 | 2015-08-27 | Société des Produits Nestlé S.A. | Inflammatory bowel disease prognostics |
AU2010266028B2 (en) * | 2009-06-25 | 2015-04-30 | Société des Produits Nestlé S.A. | Methods for diagnosing irritable bowel syndrome |
CN102858998A (en) * | 2009-11-25 | 2013-01-02 | 雀巢产品技术援助有限公司 | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
MX2012014096A (en) | 2010-06-04 | 2013-04-19 | Nestec Sa | Methods for improving inflammatory bowel disease diagnosis. |
-
2012
- 2012-10-19 AU AU2012325798A patent/AU2012325798B2/en not_active Ceased
- 2012-10-19 JP JP2014537335A patent/JP2015502740A/en active Pending
- 2012-10-19 EP EP12841790.4A patent/EP2769321B1/en active Active
- 2012-10-19 SG SG11201401536QA patent/SG11201401536QA/en unknown
- 2012-10-19 CA CA2852954A patent/CA2852954A1/en not_active Abandoned
- 2012-10-19 MX MX2014004712A patent/MX352274B/en active IP Right Grant
- 2012-10-19 WO PCT/US2012/061202 patent/WO2013059732A1/en active Application Filing
-
2013
- 2013-03-15 US US13/840,779 patent/US8715943B2/en active Active
-
2014
- 2014-03-28 US US14/229,715 patent/US20150072879A1/en not_active Abandoned
- 2014-04-22 IL IL232167A patent/IL232167A0/en unknown
-
2015
- 2015-02-04 HK HK15101185.6A patent/HK1200933A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20130225439A1 (en) | 2013-08-29 |
MX352274B (en) | 2017-11-16 |
WO2013059732A1 (en) | 2013-04-25 |
MX2014004712A (en) | 2014-11-14 |
AU2012325798B2 (en) | 2015-11-26 |
EP2769321A1 (en) | 2014-08-27 |
US8715943B2 (en) | 2014-05-06 |
CA2852954A1 (en) | 2013-04-25 |
JP2015502740A (en) | 2015-01-29 |
AU2012325798A1 (en) | 2013-05-16 |
HK1200933A1 (en) | 2015-08-14 |
IL232167A0 (en) | 2014-06-30 |
EP2769321B1 (en) | 2016-06-01 |
EP2769321A4 (en) | 2015-05-13 |
US20150072879A1 (en) | 2015-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200933A1 (en) | Methods for improving inflammatory bowel disease diagnosis | |
IL269529A (en) | Methods for diagnosing and treating inflammatory bowel disease | |
HRP20190278T1 (en) | Diagnostic methods for glaucoma | |
IL222232A0 (en) | Circulating biomarkers for disease | |
LT2997901T (en) | Imaging probe | |
EP2606353A4 (en) | Circulating biomarkers for disease | |
WO2011153501A9 (en) | Methods for improving inflammatory bowel disease diagnosis | |
EP2787982A4 (en) | Method for bowel preparation | |
HK1212220A1 (en) | Antigens associated with inflammatory bowel disease | |
GB201008541D0 (en) | Diagnostic methods | |
ZA201302402B (en) | Methods for diagnosing lyme disease | |
EP2742358A4 (en) | Methods for diagnosing cancer | |
GB201011420D0 (en) | Method for diagnosis | |
GB201223223D0 (en) | Inflammatory bowel disease | |
IL227295A0 (en) | Diagnostic method | |
AP2013007084A0 (en) | Diagnostic method | |
EP2543388A4 (en) | Drug for inflammatory bowel disease | |
EP2661625A4 (en) | Diagnostic methods | |
NZ611793A (en) | Apparatus for disease detection | |
AP2013006853A0 (en) | Biomarker for vavular heart disease | |
GB201110712D0 (en) | Diagnostic methods | |
ZA201307890B (en) | Compositions and methods for treating diagnosing and monitoring disease | |
ZA201404276B (en) | Diagnostic methods | |
IL231330A0 (en) | Methods for diagnosing cancer | |
GB201102301D0 (en) | Diagnostic methods |